NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.381) was uploaded to the NHS England Website on Wednesday 24, December 2025.
The following changes have been introduced:
Bevacizumab with FIRST LINE fluoropyrimidine-based chemotherapy (BEV11)
For metastatic or locally advanced and inoperable colorectal cancer where the following criteria have been met
Recommended for routine commissioning
NA (ISA2)
NA
Moved into routine commissioning - section B of list
Abiraterone (ABI1)
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Treatment criteria (#6, 10 and 11) updated
Abiraterone (ABI2)
For the treatment of patients with hormone-relapsed (castrate-resistant) metastatic prostate cancer with disease progression during or following treatment with docetaxel-containing chemotherapy where the following criteria have been met
Treatment criteria (#5, 9 and 10) updated
Crizotinib (CRI3)
1st or subsequent line systemic therapy for ROS1-positive inoperable locally advanced/metastatic non squamous non- small cell lung cancer where the following criteria have been met
Treatment criteria (#4 and 10) updated
Entrectinib (ENT2)
Entrectinib for ROS1-positive recurrent locally advanced or metastatic non-small- cell lung cancer previously untreated with a ROS1 inhibitor therapy where the following criteria have been met
Treatment criteria (#3, 4, 5, 6, 7, 8 and 9) updated
Eribulin (ERIB1)
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more lines of systemic anti-cancer treatment where the following criteria have been met
Title and treatment criteria (#3 and 4) updated
Enzalutamide (ENZ4)
Enzalutamide for the treatment of patients with hormone-relapsed (castrate- resistant) metastatic prostate cancer before chemotherapy is indicated where the following criteria have been met
Treatment criteria (#5, 8 and 9) updated
Enzalutamide (ENZ5)
Enzalutamide for the treatment of patients with hormone-relapsed (castrate- resistant) metastatic prostate cancer with disease progression during or following treatment with docetaxel-containing chemotherapy where the following criteria have been met
Treatment criteria (#6, 9 and 10) updated
Fedratinib (FED1)
For the treatment of patients with myelofibrosis previously treated with ruxolitinib where the following criteria have been met
Treatment criteria (#5, 9, 10 and 11) updated
Tivozanib (TIV1)
The treatment of advanced renal cell carcinoma where all the following criteria are met:
Treatment criteria (#5, 9 and 10) updated